Breast cancer patients with the PIK3CA genetic mutation respond poorer to traditional treatment and have a worse survival rate. Alarmingly, most women don't know this.
A genetic test can potentially change their disease outcome. However, tests for the PIK3CA mutation are not publicly funded in Hong Kong, which means it is an 'extra step' that patients may miss during their treatment journey. Novartis wanted to empo